16 / 46
•
STRATIFICATION: High Volume Disease (yes vs. no), Study Site, Concomitant
“Anti-Resorptive” Therapy to Delay SRE, Co-Morbidities, Early Use of Docetaxel
Enzalutamide
160 mg QD
+ LHRHa
(or orchidectomy)
until progression
n=1125
Metastatic prostate
cancer
ECOG 0–2
Commencing ADT
NSAA + LHRHa
(or orchidectomy)
until progression
R
1:1
SPONSOR: University of Sydney (Astellas IIT;
Study Chairs - Chris Sweeney (Dana Farber) and
Ian Davis (Eastern Health Box Hill Hospital))
PRIMARY COMPLETION DATE: September 2020
AUS, UK, Canada, US, IRL, NZ